Johnson & Johnson MedTech launches CEREGLIDE 92 Catheter System for Acute ischemic stroke Ruchika Sharma13 Feb 2025 4:54 PM ISTIrvine: Johnson & Johnson MedTech, an emerging leader in neurovascular care, has announced the launch of the CEREGLIDE 92 Catheter System, a...
European Commission authorises ViiV Healthcare Vocabria plus Rekambys for HIV treatment in adolescents Ruchika Sharma2 Feb 2025 1:30 PM ISTLondon: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,...
JnJ Spravato gets USFDA nod as monotherapy for adults with treatment-resistant depression Ruchika Sharma22 Jan 2025 11:35 AM ISTTitusville: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application...
JnJ initiates submission of New Drug Application with USFDA for TAR-200 for BCG-unresponsive high-risk non-muscle-invasive bladder cancer Ruchika Sharma16 Jan 2025 12:30 PM ISTRaritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug...
JnJ to acquire Intra-Cellular Therapies for USD 14.6 billion Ruchika Sharma15 Jan 2025 11:30 AM ISTNew Brunswick: Johnson & Johnson and Intra-Cellular Therapies, Inc. have announced that they have entered into a definitive agreement under...
JnJ Nipocalimab gets USFDA Priority Review designation for generalized myasthenia gravis Ruchika Sharma12 Jan 2025 3:30 PM ISTSpring House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review designation...
JnJ temporarily pauses rollout of Varipulse heart device in US Ruchika Sharma11 Jan 2025 5:35 PM ISTJohnson & Johnson has announced a temporarily pause in the rollout of its Varipulse heart device in the United States as it investigates four...
JnJ Posdinemab gets USFDA Fast Track Designation for treatment of Alzheimer's disease Ruchika Sharma9 Jan 2025 1:30 PM ISTPosdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific phosphorylated tau.
European Commission approves Janssen-Cilag International Rybrevant, Lazcluze combo for first-line treatment of lung cancer Ruchika Sharma31 Dec 2024 11:30 AM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has approved a Type II...
JnJ enters licensing agreement for global development, manufacturing, commercialization of STAT6 program from Kaken Pharma Ruchika Sharma27 Dec 2024 10:00 AM ISTNew Brunswick: Johnson & Johnson has announced that it has entered into an exclusive licensing agreement for the global...
JnJ seeks USFDA approval for Simponi to treat pediatric ulcerative colitis Ruchika Sharma19 Dec 2024 12:42 PM ISTDeveloped by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.
Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
